Septerna, Inc. SEPN 深 滬
已收盤 08-22 16:00:00 美东时间
11.99
+0.290
+2.48%
華盛通- 最 高12.74
- 今 開11.84
- 成交量 36.30万股
- 最 低 11.73
- 昨 收 11.70
- 總市值 5.34亿
- 52周最高 28.99
- 市盈率 靜 --
- 換手率 0.81%
- 52周最低 4.17
- 委 比 -99.54%
- 總股本 4455.83万
- 歷史最高 28.99
- 量 比 1.48
- 振 幅 8.63%
- 歷史最低 4.17
- 每 手 1
- 風險率 6.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Septerna Begins Phase 1 Trial for SEP-631
The latest announcement is out from Septerna, Inc. ( ($SEPN) ). On August 21, 2...
08-21 20:58
Septerna Announces Dosing Of First Participants In Phase 1 Clinical Trial Of SEP-631, Selective Oral Small Molecule MRGPRX2 NAM Being Developed For Treatment Of CSU And Other Mast Cell-Driven Diseases
Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 clinical
08-21 20:08
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
Septerna, Inc. has initiated a Phase 1 clinical trial for SEP-631, a novel oral treatment targeting chronic spontaneous urticaria and mast cell-driven diseases. The trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SEP-631 in healthy volunteers. As a selective negative allosteric modulator of MRGPRX2, SEP-631 inhibits mast cell activation and degranulation, offering potential relief for millions affected b...
08-21 12:00
跨国药企洞察｜左手诉讼 右手创新 发起132诉讼的诺和诺德能否赢得“反击战”？
（来源：动脉新医药） 编者按： 全球视野下的跨国药企深度洞察——创新、博弈与中国答卷 在全球医药产业发展的宏大叙事中，跨国药企始终扮演着关键角色——他们...
08-15 17:54
礼来13亿美元投资了背靠英伟达的AI制药商
GPCR是最大且最多样化的细胞膜受体家族，数百种不同的GPCR在人体几乎所有器官系统中都发挥着生理机制调节作用。 当地时间8月14日，礼来宣布与美国AI制药公司...
08-15 15:12
Septerna Q2 EPS $(0.56) Misses $(0.34) Estimate, Sales $119.000K Miss $6.800M Estimate
Septerna (NASDAQ:SEPN) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.34) by 66.17 percent. The company reported quarterly sales of $119.000 thousand which missed the
08-12 04:25
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
Septerna Inc. reported Q2 2025 results, highlighting key milestones: advancing PTH1R agonist program for hypoparathyroidism with a development candidate selection expected in Q3 2025 and Phase 1 trial in 2026; initiating Phase 1 trial for SEP-631, an oral MRGPRX2 NAM for mast cell diseases; and $379.2M cash as of June 30, 2025. The company also announced Liz Bhatt's promotion to President and a collaboration with Novo Nordisk to develop therapies...
08-11 20:01
诺和诺德2025Q2业绩电话会高管解读财报
拉尔斯·弗鲁尔加德·约根森 2025年前六个月，我们的销售额增长了18%，营业利润增长了29%。正如上周宣布的那样，诺和诺德已下调2025年全年业绩预期，较今年...
08-07 10:45
Septerna Appoints Liz Bhatt as New President
Septerna, Inc. ( ($SEPN) ) has provided an announcement. On July 30, 2025, Sept...
08-05 04:47
